On March 23, 2026, Telomir Pharmaceuticals, Inc. shareholders approved increasing shares in the Omnibus Incentive Plan from 6.5M to 11.5M and various corporate proposals including the acquisition of Teli Pharmaceuticals. A total of 34.38M shares were outstanding as of January 23, 2026, with 17.59M votes counted during the meeting.